Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Localized doxycycline delivery via polymeric nanoparticles anchored to electrospun PCL microfiber patch for MMP-2 inhibition in abdominal aortic aneurysm

  • Bofill Bonet, Carles
  • Febas, Germán
  • Artigues Cladera, Margalida
  • Moreno-Jimenez, Ines
  • Balà Palasí, Noemí
  • Martorell, Jordi
  • Borrós, Salvador
  • Fornaguera, Cristina
Doxycycline (DOXY) is a well-established antibiotic that has recently shown potential in inhibiting matrix metalloproteinase-2 (MMP-2), a key enzyme involved in the progression of abdominal aortic aneurysms (AAA). However, the controlled delivery of DOXY to the aneurysm site, with sustained release and minimal systemic exposure, remains a critical challenge in therapeutic development. To address this, we developed a targeted drug delivery platform based on polymeric nanoparticles (NPs), prepared from water-in-oil-in-water nano-emulsions, encapsulating DOXY and are covalently attached to electrospun ε-poly(caprolactone) (ε-PCL) microfibers. This system was designed to enable local, sustained drug release in the inner wall of aorta while preserving the mechanical properties of the aortic wall. The ε-PCL electrospun microfibers from the patch were first functionalized using oxygen cold plasma treatment, creating free radicals that enabled covalent bonding with chemical groups on the outer layer of DOXY-loaded poly(lactic-co-glycolic acid) (PLGA) NPs. This strategy allowed for robust immobilization of the NPs onto the microfibers surface, forming a composite system capable of localized and controlled drug release over time. Unlike traditional delivery approaches, this method ensures site-specific action of DOXY directly at the aneurysmal tissue, minimizing systemic circulation and reducing off-target toxicity. The platform not only provides a stable drug reservoir but also offers intrinsic biomechanical reinforcement, which is critical in AAA condition. This innovative delivery system represents a significant advance in the localized treatment of vascular disorders. It offers a biocompatible, biodegradable, and precisely targeted therapeutic approach, with potential to reduce the need for surgical intervention and limits the adverse effects associated with systemic drug administration., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Transforming tumor cells into professional antigen-presenting cells using poly(β-amino ester) nanoparticles to deliver CD80-encoding mRNA

  • Binder, Amanda Katharina
  • Bremm, Franziska
  • Feuchter, Niklas
  • Torres-Coll, Antoni
  • Kübel, Sabrina
  • Berking, Carola
  • Borrós, Salvador
  • Fornaguera, Cristina
  • Schaft, Niels
  • Dörrie, Jan
Effective T-cell activation requires both antigen recognition and co-stimulatory signaling. However, tumor cells typically lack the necessary co-stimulatory molecules, rendering T-cell receptor engagement with tumor antigens insufficient to induce potent anti-tumor immune responses. To overcome this limitation, we converted tumor cells into professional antigen-presenting cell (APC)-like cells by equipping them with the co-stimulatory molecule CD80. Electroporation of melanoma and lung cancer cell lines with CD80-encoding mRNA significantly increased their ability to stimulate tumor-antigen-specific T cells, as indicated by increased activation markers and cytokine secretion. Most importantly, CD80 expression converted melanoma cells into APC-like cells capable of priming and expanding naïve T cells that recognize endogenous tumor antigens. To enable clinical application, we subsequently used poly-(beta aminoester) (pBAE) polymers, which efficiently encapsulate mRNA into nanometric polyplexes. As previously reported, pBAE nanoparticles (NPs) efficiently penetrate plasma membranes and escape endosomal degradation both in vitro and in vivo. Here, we evaluated pBAE NPs encapsulating GFP-encoding mRNA in human cell lines derived from melanoma, lung cancer, leukemia, adenocarcinoma, uveal melanoma, and Merkel cell carcinoma. The pBAE NPs effectively transfected adherent tumor cells, and tumor spheroids in vitro and in ovo. When delivering CD80 mRNA, NPs achieved expression rates of more than 50% in most cell lines, which lasted for at least 72 h. Here as well, nanoparticle-mediated CD80 expression enabled melanoma cells to prime and expand naïve T cells recognizing endogenous tumor antigens. Importantly, T cells primed by CD80-expressing tumor cells were also capable of killing tumor cells that had not been transfected. In line with these findings, T cells stimulated with untransfected tumor cells showed high levels of checkpoint receptors CTLA-4 and PD-1, whereas the expression was significantly lower when using CD80-transfected tumor cells. This proof-of-concept study indicates that conversion of tumor cells into professional APC-like cells with CD80 mRNA is feasible and results in potent anti-tumor CD8+ T-cell responses. With the use of mRNA-loaded pBAEs, the prerequisites for a future application in vivo are given. Therefore, the application of pBAE NPs encapsulating CD80 mRNA to specifically transfect tumor cells presents a new promising strategy for the in vivo treatment of various cancers., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

A dual QTOF–QTrap analytical platform for comprehensive tracking of doxycycline and its degradation byproducts in biological and nanoparticle-based delivery systems

  • Bofill Bonet, Carles
  • Artigues Cladera, Margalida
  • Moreno-Jimenez, Ines
  • Balà, Noemí
  • Martorell, Jordi
  • Fornaguera, Cristina
  • Borrós, Salvador
Doxycycline (DOX) is a second-generation tetracycline antibiotic extensively used in clinical practice, not only for its antimicrobial activity but also for its emerging therapeutic potential in modulating extracellular matrix (ECM) in remodeling processes. Increasing evidence supports its role in attenuating pathological conditions associated with ECM degradation by targeting matrix metalloproteinases type 2 (MMP-2), including cancer progression and abdominal aortic aneurysm (AAA). However, DOX exhibits limited stability in aqueous and semi-physiological environments, undergoing hydrolysis and oxidative reactions that lead to the generation of multiple degradation byproducts, thereby compromising its efficacy and safety profile. In this study, we systematically mapped the degradation pathways of DOX under rigorously controlled physicochemical and biological conditions. High-resolution QTOF mass spectrometry operating in SWATH data-independent acquisition mode enabled unbiased identification of multiple, structurally distinct degradation byproducts, as well as the DOX parent compound, using curated metabolite libraries from SCIEX platform. Building on this annotation step, we established a complementary QTrap-based targeted workflow to quantify low-abundance metabolites intra- and extracellular through isotope-specific transitions derived from the QTOF analysis and to monitor their temporal kinetics with high sensitivity. Together, this integrated analytical strategy provides refined insight into the intrinsic instability of DOX and its potential biological consequences. To translate degradation mapping into a biologically relevant context, OM-PLGA NPs were incorporated as a controlled delivery platform that modulates DOX exposure, slows spontaneous degradation, and creates the matrix conditions required to validate the sensitivity of the QTRAP workflow in complex cellular environments. This validation demonstrated that OM-PLGA nanoparticles not only preserve DOX in its bioactive form through microenvironmental shielding, but also results in enhanced pharmacological activity, particularly sustained inhibition of MMP-2, a central enzyme in AAA-associated ECM remodeling. Together, these results highlight the dual value of the advanced analytical workflow and the nanocarrier strategy, demonstrating how integrating high-resolution mass spectrometry with nanoparticle engineering overcomes the intrinsic instability of DOX and provides deeper mechanistic insight across both analytical and biological dimensions., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Transforming tumor cells into professional antigen-presenting cells using poly(β-amino ester) nanoparticles to deliver CD80-encoding mRNA

  • Binder, Amanda Katharina
  • Bremm, Franziska
  • Feuchter, Niklas
  • Torres-Coll, Antoni
  • Kübel, Sabrina
  • Berking, Carola
  • Borrós, Salvador
  • Fornaguera, Cristina
  • Schaft, Niels
  • Dörrie, Jan
Effective T-cell activation requires both antigen recognition and co-stimulatory signaling. However, tumor cells typically lack the necessary co-stimulatory molecules, rendering T-cell receptor engagement with tumor antigens insufficient to induce potent anti-tumor immune responses. To overcome this limitation, we converted tumor cells into professional antigen-presenting cell (APC)-like cells by equipping them with the co-stimulatory molecule CD80. Electroporation of melanoma and lung cancer cell lines with CD80-encoding mRNA significantly increased their ability to stimulate tumor-antigen-specific T cells, as indicated by increased activation markers and cytokine secretion. Most importantly, CD80 expression converted melanoma cells into APC-like cells capable of priming and expanding naïve T cells that recognize endogenous tumor antigens. To enable clinical application, we subsequently used poly-(beta aminoester) (pBAE) polymers, which efficiently encapsulate mRNA into nanometric polyplexes. As previously reported, pBAE nanoparticles (NPs) efficiently penetrate plasma membranes and escape endosomal degradation both in vitro and in vivo. Here, we evaluated pBAE NPs encapsulating GFP-encoding mRNA in human cell lines derived from melanoma, lung cancer, leukemia, adenocarcinoma, uveal melanoma, and Merkel cell carcinoma. The pBAE NPs effectively transfected adherent tumor cells, and tumor spheroids in vitro and in ovo. When delivering CD80 mRNA, NPs achieved expression rates of more than 50% in most cell lines, which lasted for at least 72 h. Here as well, nanoparticle-mediated CD80 expression enabled melanoma cells to prime and expand naïve T cells recognizing endogenous tumor antigens. Importantly, T cells primed by CD80-expressing tumor cells were also capable of killing tumor cells that had not been transfected. In line with these findings, T cells stimulated with untransfected tumor cells showed high levels of checkpoint receptors CTLA-4 and PD-1, whereas the expression was significantly lower when using CD80-transfected tumor cells. This proof-of-concept study indicates that conversion of tumor cells into professional APC-like cells with CD80 mRNA is feasible and results in potent anti-tumor CD8+ T-cell responses. With the use of mRNA-loaded pBAEs, the prerequisites for a future application in vivo are given. Therefore, the application of pBAE NPs encapsulating CD80 mRNA to specifically transfect tumor cells presents a new promising strategy for the in vivo treatment of various cancers., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

From nucleotides to intact transcripts through oligonucleotides: Integrated chromatographic strategies for therapeutic mRNA characterization

  • Losada Baranera, Mar
  • GOTOR, GEMMA
  • Borrós, Salvador
  • Fornaguera, Cristina
Messenger RNA (mRNA) has emerged as a transformative modality for modern therapeutics, including vaccines and gene therapies. Ensuring the quality, safety, and efficacy of mRNA products requires the evaluation of critical quality attributes (CQAs) such as sequence integrity, nucleotide modifications, purity, and structural stability. The growing complexity of modified mRNA therapeutics highlights the need for robust and orthogonal analytical strategies. This review summarizes liquid chromatography (LC)-based workflows tailored for mRNA characterization including UV detection and mass spectrometry (MS) strategies. These include nucleoside-level analysis to identify chemical modifications and impurities, partial digestion with oligonucleotide mapping to assess sequence coverage and localization of modifications, and intact mRNA analysis to evaluate global structural integrity and encapsulation efficiency. Case studies illustrate practical applications by directly linking analytical workflows to specific CQAs and regulatory-relevant attributes. By leveraging advances in chromatography and mass spectrometry—including bioinert stationary phases, high-resolution detection, and ion-pairing strategies—these studies enable robust analysis of highly polar, charged, and high-molecular-weight mRNA species. The integration of complementary chromatographic and MS-based workflows supports comprehensive characterization, facilitates regulatory compliance, and informs process and formulation development, ultimately providing a coherent framework for quality control in emerging mRNA therapeutics., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Nucleic acid-loaded poly(beta-aminoester) nanoparticles for cancer nano-immuno therapeutics, the good, the bad, and the future

  • Magana Rodriguez, Jose Rodrigo
  • Guerra-Rebollo, Marta
  • Borrós, Salvador
  • Fornaguera, Cristina
Immunotherapy has emerged as a promising approach to cancer treatment, offering improved survival rates and enhanced patients’ quality of life. However, realizing the full potential of immunotherapy in clinical practice remains a challenge, as there is still plenty of room for modulating the complexity of the human immune system in favor of an antitumor immunogenicity. Nanotechnology, with its unique properties, holds promise in augmenting the efficacy of cancer immunotherapies in biotherapeutic protection and site- and time-controlled delivery of the immune modulator biologicals. Polymeric nanoparticles are promising biomaterials among different nanocarriers thanks to their robustness, versatility, and cost-efficient design and production. This perspective paper overviews critical concepts in nanometric advanced delivery systems applied to cancer immunotherapy. We focus on a detailed exploration of the current state of the art and trends in using poly(beta-aminoester) (pBAE) polymers for nucleic acid-based antitumor immunotherapies. Through different examples of the use of pBAE polymers reported in the literature, we revise the main advantages these polymers offer and some challenges to overcome. Finally, the paper provides insights and predictions on the path toward the clinical implementation of cancer nano-immunotherapies, highlighting the potential of pBAE polymers for advancements in this field., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Unveiling the contribution of histidine-end-terminal pBAEs to endosomal escape using super-resCLEM imaging

  • Navalón López, María
  • Andrian, Teodora
  • Albertazzi, Lorenzo
  • Borrós, Salvador
  • Fornaguera, Cristina
  • Pujals, Sílvia
The success of gene therapy focuses on the development of efficient and safe carriers capable of overcoming cellular barriers to deliver genetic material to the nucleus. Poly(beta-amino ester) nanoparticles (pβAE NPs) are promising cationic polymers that can complex nucleic acids to form polyplexes, facilitating intracellular delivery. Among the key intracellular hurdles, endosomal escape remains one of the most critical and debated steps. While the incorporation of histidine into polyplex formulations has been proposed to enhance endosomal escape via proton buffering, definitive evidence of this process has remained elusive. To address this gap, a super-resolution correlative light and electron microscopy (CLEM) approach was employed to decipher the intracellular trafficking of pβAE NPs. Specifically, we compared two pβAE formulations, one incorporating a histidine-arginine end-capping structure (RH) and a control containing only arginine end-capping (R). Our findings revealed that RH polyplexes efficiently escaped endosomes at early timepoints and achieved cytosolic localization, whereas R polyplexes predominantly remained trapped within endo-lysosomal compartments, ultimately undergoing exocytosis or degradation, as confirmed by lysosome-specific staining. This study provides, for the first time, direct high-resolution evidence of histidine-mediated endosomal escape in gene therapy, underscoring the role of histidine in overcoming intracellular barriers. Moreover, it highlights the power of super-resolution correlative imaging techniques in elucidating the nanoscale trafficking of gene delivery systems, enabling more rational design of next generation nanocarriers., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

From nucleotides to intact transcripts through oligonucleotides: Integrated chromatographic strategies for therapeutic mRNA characterization

  • Losada Baranera, Mar
  • GOTOR, GEMMA
  • Borrós, Salvador
  • Fornaguera, Cristina
Messenger RNA (mRNA) has emerged as a transformative modality for modern therapeutics, including vaccines and gene therapies. Ensuring the quality, safety, and efficacy of mRNA products requires the evaluation of critical quality attributes (CQAs) such as sequence integrity, nucleotide modifications, purity, and structural stability. The growing complexity of modified mRNA therapeutics highlights the need for robust and orthogonal analytical strategies. This review summarizes liquid chromatography (LC)-based workflows tailored for mRNA characterization including UV detection and mass spectrometry (MS) strategies. These include nucleoside-level analysis to identify chemical modifications and impurities, partial digestion with oligonucleotide mapping to assess sequence coverage and localization of modifications, and intact mRNA analysis to evaluate global structural integrity and encapsulation efficiency. Case studies illustrate practical applications by directly linking analytical workflows to specific CQAs and regulatory-relevant attributes. By leveraging advances in chromatography and mass spectrometry—including bioinert stationary phases, high-resolution detection, and ion-pairing strategies—these studies enable robust analysis of highly polar, charged, and high-molecular-weight mRNA species. The integration of complementary chromatographic and MS-based workflows supports comprehensive characterization, facilitates regulatory compliance, and informs process and formulation development, ultimately providing a coherent framework for quality control in emerging mRNA therapeutics., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Transforming tumor cells into professional antigen-presenting cells using poly(β-amino ester) nanoparticles to deliver CD80-encoding mRNA

  • Binder, Amanda Katharina
  • Bremm, Franziska
  • Feuchter, Niklas
  • Torres-Coll, Antoni
  • Kübel, Sabrina
  • Berking, Carola
  • Borrós, Salvador
  • Fornaguera, Cristina
  • Schaft, Niels
  • Dörrie, Jan
Effective T-cell activation requires both antigen recognition and co-stimulatory signaling. However, tumor cells typically lack the necessary co-stimulatory molecules, rendering T-cell receptor engagement with tumor antigens insufficient to induce potent anti-tumor immune responses. To overcome this limitation, we converted tumor cells into professional antigen-presenting cell (APC)-like cells by equipping them with the co-stimulatory molecule CD80. Electroporation of melanoma and lung cancer cell lines with CD80-encoding mRNA significantly increased their ability to stimulate tumor-antigen-specific T cells, as indicated by increased activation markers and cytokine secretion. Most importantly, CD80 expression converted melanoma cells into APC-like cells capable of priming and expanding naïve T cells that recognize endogenous tumor antigens. To enable clinical application, we subsequently used poly-(beta aminoester) (pBAE) polymers, which efficiently encapsulate mRNA into nanometric polyplexes. As previously reported, pBAE nanoparticles (NPs) efficiently penetrate plasma membranes and escape endosomal degradation both in vitro and in vivo. Here, we evaluated pBAE NPs encapsulating GFP-encoding mRNA in human cell lines derived from melanoma, lung cancer, leukemia, adenocarcinoma, uveal melanoma, and Merkel cell carcinoma. The pBAE NPs effectively transfected adherent tumor cells, and tumor spheroids in vitro and in ovo. When delivering CD80 mRNA, NPs achieved expression rates of more than 50% in most cell lines, which lasted for at least 72 h. Here as well, nanoparticle-mediated CD80 expression enabled melanoma cells to prime and expand naïve T cells recognizing endogenous tumor antigens. Importantly, T cells primed by CD80-expressing tumor cells were also capable of killing tumor cells that had not been transfected. In line with these findings, T cells stimulated with untransfected tumor cells showed high levels of checkpoint receptors CTLA-4 and PD-1, whereas the expression was significantly lower when using CD80-transfected tumor cells. This proof-of-concept study indicates that conversion of tumor cells into professional APC-like cells with CD80 mRNA is feasible and results in potent anti-tumor CD8+ T-cell responses. With the use of mRNA-loaded pBAEs, the prerequisites for a future application in vivo are given. Therefore, the application of pBAE NPs encapsulating CD80 mRNA to specifically transfect tumor cells presents a new promising strategy for the in vivo treatment of various cancers., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Nucleic acid-loaded poly(beta-aminoester) nanoparticles for cancer nano-immuno therapeutics, the good, the bad, and the future

  • Magana Rodriguez, Jose Rodrigo
  • Guerra-Rebollo, Marta
  • Borrós, Salvador
  • Fornaguera, Cristina
Immunotherapy has emerged as a promising approach to cancer treatment, offering improved survival rates and enhanced patients’ quality of life. However, realizing the full potential of immunotherapy in clinical practice remains a challenge, as there is still plenty of room for modulating the complexity of the human immune system in favor of an antitumor immunogenicity. Nanotechnology, with its unique properties, holds promise in augmenting the efficacy of cancer immunotherapies in biotherapeutic protection and site- and time-controlled delivery of the immune modulator biologicals. Polymeric nanoparticles are promising biomaterials among different nanocarriers thanks to their robustness, versatility, and cost-efficient design and production. This perspective paper overviews critical concepts in nanometric advanced delivery systems applied to cancer immunotherapy. We focus on a detailed exploration of the current state of the art and trends in using poly(beta-aminoester) (pBAE) polymers for nucleic acid-based antitumor immunotherapies. Through different examples of the use of pBAE polymers reported in the literature, we revise the main advantages these polymers offer and some challenges to overcome. Finally, the paper provides insights and predictions on the path toward the clinical implementation of cancer nano-immunotherapies, highlighting the potential of pBAE polymers for advancements in this field., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A dual QTOF–QTrap analytical platform for comprehensive tracking of doxycycline and its degradation byproducts in biological and nanoparticle-based delivery systems

  • Bofill Bonet, Carles
  • Artigues Cladera, Margalida
  • Moreno-Jimenez, Ines
  • Balà, Noemí
  • Martorell, Jordi
  • Fornaguera, Cristina
  • Borrós, Salvador
Doxycycline (DOX) is a second-generation tetracycline antibiotic extensively used in clinical practice, not only for its antimicrobial activity but also for its emerging therapeutic potential in modulating extracellular matrix (ECM) in remodeling processes. Increasing evidence supports its role in attenuating pathological conditions associated with ECM degradation by targeting matrix metalloproteinases type 2 (MMP-2), including cancer progression and abdominal aortic aneurysm (AAA). However, DOX exhibits limited stability in aqueous and semi-physiological environments, undergoing hydrolysis and oxidative reactions that lead to the generation of multiple degradation byproducts, thereby compromising its efficacy and safety profile. In this study, we systematically mapped the degradation pathways of DOX under rigorously controlled physicochemical and biological conditions. High-resolution QTOF mass spectrometry operating in SWATH data-independent acquisition mode enabled unbiased identification of multiple, structurally distinct degradation byproducts, as well as the DOX parent compound, using curated metabolite libraries from SCIEX platform. Building on this annotation step, we established a complementary QTrap-based targeted workflow to quantify low-abundance metabolites intra- and extracellular through isotope-specific transitions derived from the QTOF analysis and to monitor their temporal kinetics with high sensitivity. Together, this integrated analytical strategy provides refined insight into the intrinsic instability of DOX and its potential biological consequences. To translate degradation mapping into a biologically relevant context, OM-PLGA NPs were incorporated as a controlled delivery platform that modulates DOX exposure, slows spontaneous degradation, and creates the matrix conditions required to validate the sensitivity of the QTRAP workflow in complex cellular environments. This validation demonstrated that OM-PLGA nanoparticles not only preserve DOX in its bioactive form through microenvironmental shielding, but also results in enhanced pharmacological activity, particularly sustained inhibition of MMP-2, a central enzyme in AAA-associated ECM remodeling. Together, these results highlight the dual value of the advanced analytical workflow and the nanocarrier strategy, demonstrating how integrating high-resolution mass spectrometry with nanoparticle engineering overcomes the intrinsic instability of DOX and provides deeper mechanistic insight across both analytical and biological dimensions., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Localized doxycycline delivery via polymeric nanoparticles anchored to electrospun PCL microfiber patch for MMP-2 inhibition in abdominal aortic aneurysm

  • Bofill Bonet, Carles
  • Febas, Germán
  • Artigues Cladera, Margalida
  • Moreno-Jimenez, Ines
  • Balà Palasí, Noemí
  • Martorell, Jordi
  • Borrós, Salvador
  • Fornaguera, Cristina
Doxycycline (DOXY) is a well-established antibiotic that has recently shown potential in inhibiting matrix metalloproteinase-2 (MMP-2), a key enzyme involved in the progression of abdominal aortic aneurysms (AAA). However, the controlled delivery of DOXY to the aneurysm site, with sustained release and minimal systemic exposure, remains a critical challenge in therapeutic development. To address this, we developed a targeted drug delivery platform based on polymeric nanoparticles (NPs), prepared from water-in-oil-in-water nano-emulsions, encapsulating DOXY and are covalently attached to electrospun ε-poly(caprolactone) (ε-PCL) microfibers. This system was designed to enable local, sustained drug release in the inner wall of aorta while preserving the mechanical properties of the aortic wall. The ε-PCL electrospun microfibers from the patch were first functionalized using oxygen cold plasma treatment, creating free radicals that enabled covalent bonding with chemical groups on the outer layer of DOXY-loaded poly(lactic-co-glycolic acid) (PLGA) NPs. This strategy allowed for robust immobilization of the NPs onto the microfibers surface, forming a composite system capable of localized and controlled drug release over time. Unlike traditional delivery approaches, this method ensures site-specific action of DOXY directly at the aneurysmal tissue, minimizing systemic circulation and reducing off-target toxicity. The platform not only provides a stable drug reservoir but also offers intrinsic biomechanical reinforcement, which is critical in AAA condition. This innovative delivery system represents a significant advance in the localized treatment of vascular disorders. It offers a biocompatible, biodegradable, and precisely targeted therapeutic approach, with potential to reduce the need for surgical intervention and limits the adverse effects associated with systemic drug administration., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Unveiling the contribution of histidine-end-terminal pBAEs to endosomal escape using super-resCLEM imaging

  • Navalón López, María
  • Andrian, Teodora
  • Albertazzi, Lorenzo
  • Borrós, Salvador
  • Fornaguera, Cristina
  • Pujals, Sílvia
The success of gene therapy focuses on the development of efficient and safe carriers capable of overcoming cellular barriers to deliver genetic material to the nucleus. Poly(beta-amino ester) nanoparticles (pβAE NPs) are promising cationic polymers that can complex nucleic acids to form polyplexes, facilitating intracellular delivery. Among the key intracellular hurdles, endosomal escape remains one of the most critical and debated steps. While the incorporation of histidine into polyplex formulations has been proposed to enhance endosomal escape via proton buffering, definitive evidence of this process has remained elusive. To address this gap, a super-resolution correlative light and electron microscopy (CLEM) approach was employed to decipher the intracellular trafficking of pβAE NPs. Specifically, we compared two pβAE formulations, one incorporating a histidine-arginine end-capping structure (RH) and a control containing only arginine end-capping (R). Our findings revealed that RH polyplexes efficiently escaped endosomes at early timepoints and achieved cytosolic localization, whereas R polyplexes predominantly remained trapped within endo-lysosomal compartments, ultimately undergoing exocytosis or degradation, as confirmed by lysosome-specific staining. This study provides, for the first time, direct high-resolution evidence of histidine-mediated endosomal escape in gene therapy, underscoring the role of histidine in overcoming intracellular barriers. Moreover, it highlights the power of super-resolution correlative imaging techniques in elucidating the nanoscale trafficking of gene delivery systems, enabling more rational design of next generation nanocarriers., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Transforming tumor cells into professional antigen-presenting cells using poly(β-amino ester) nanoparticles to deliver CD80-encoding mRNA

  • Binder, Amanda Katharina
  • Bremm, Franziska
  • Feuchter, Niklas
  • Torres-Coll, Antoni
  • Kübel, Sabrina
  • Berking, Carola
  • Borrós, Salvador
  • Fornaguera, Cristina
  • Schaft, Niels
  • Dörrie, Jan
Effective T-cell activation requires both antigen recognition and co-stimulatory signaling. However, tumor cells typically lack the necessary co-stimulatory molecules, rendering T-cell receptor engagement with tumor antigens insufficient to induce potent anti-tumor immune responses. To overcome this limitation, we converted tumor cells into professional antigen-presenting cell (APC)-like cells by equipping them with the co-stimulatory molecule CD80. Electroporation of melanoma and lung cancer cell lines with CD80-encoding mRNA significantly increased their ability to stimulate tumor-antigen-specific T cells, as indicated by increased activation markers and cytokine secretion. Most importantly, CD80 expression converted melanoma cells into APC-like cells capable of priming and expanding naïve T cells that recognize endogenous tumor antigens. To enable clinical application, we subsequently used poly-(beta aminoester) (pBAE) polymers, which efficiently encapsulate mRNA into nanometric polyplexes. As previously reported, pBAE nanoparticles (NPs) efficiently penetrate plasma membranes and escape endosomal degradation both in vitro and in vivo. Here, we evaluated pBAE NPs encapsulating GFP-encoding mRNA in human cell lines derived from melanoma, lung cancer, leukemia, adenocarcinoma, uveal melanoma, and Merkel cell carcinoma. The pBAE NPs effectively transfected adherent tumor cells, and tumor spheroids in vitro and in ovo. When delivering CD80 mRNA, NPs achieved expression rates of more than 50% in most cell lines, which lasted for at least 72 h. Here as well, nanoparticle-mediated CD80 expression enabled melanoma cells to prime and expand naïve T cells recognizing endogenous tumor antigens. Importantly, T cells primed by CD80-expressing tumor cells were also capable of killing tumor cells that had not been transfected. In line with these findings, T cells stimulated with untransfected tumor cells showed high levels of checkpoint receptors CTLA-4 and PD-1, whereas the expression was significantly lower when using CD80-transfected tumor cells. This proof-of-concept study indicates that conversion of tumor cells into professional APC-like cells with CD80 mRNA is feasible and results in potent anti-tumor CD8+ T-cell responses. With the use of mRNA-loaded pBAEs, the prerequisites for a future application in vivo are given. Therefore, the application of pBAE NPs encapsulating CD80 mRNA to specifically transfect tumor cells presents a new promising strategy for the in vivo treatment of various cancers., info:eu-repo/semantics/publishedVersion